Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) had its price target trimmed by Royal Bank Of Canada from $210.00 to $195.00 in a research note released on Wednesday. The brokerage currently has an outperform rating on the specialty pharmaceutical company’s stock.

Several other equities analysts have also issued reports on the company. Stifel Nicolaus reiterated a buy rating and issued a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, October 26th. Piper Jaffray Companies set a $177.00 price objective on Jazz Pharmaceuticals PLC and gave the company a buy rating in a research report on Saturday, October 21st. Cantor Fitzgerald reiterated a buy rating on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, August 29th. Deutsche Bank AG set a $178.00 price objective on Jazz Pharmaceuticals PLC and gave the company a buy rating in a research report on Monday, July 17th. Finally, FBR & Co started coverage on Jazz Pharmaceuticals PLC in a research report on Thursday, October 19th. They issued a buy rating and a $206.00 price objective for the company. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $180.13.

Shares of Jazz Pharmaceuticals PLC (JAZZ) traded up $3.39 during mid-day trading on Wednesday, hitting $138.70. The stock had a trading volume of 551,900 shares, compared to its average volume of 589,600. The company has a current ratio of 3.10, a quick ratio of 2.49 and a debt-to-equity ratio of 0.63. Jazz Pharmaceuticals PLC has a one year low of $99.28 and a one year high of $163.75. The company has a market cap of $8,315.20, a PE ratio of 17.40, a PEG ratio of 0.84 and a beta of 1.00.

WARNING: This piece was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/11/12/jazz-pharmaceuticals-plc-jazz-price-target-cut-to-195-00-by-analysts-at-royal-bank-of-canada.html.

In other news, SVP Paul Treacy sold 1,304 shares of the stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $143.32, for a total value of $186,889.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $144.38, for a total value of $28,876.00. Following the completion of the sale, the executive vice president now directly owns 21,996 shares of the company’s stock, valued at approximately $3,175,782.48. The disclosure for this sale can be found here. In the last three months, insiders sold 3,855 shares of company stock valued at $571,374. 4.30% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Schroder Investment Management Group bought a new stake in Jazz Pharmaceuticals PLC in the 3rd quarter valued at $52,571,000. Achmea Investment Management B.V. raised its stake in Jazz Pharmaceuticals PLC by 282.0% in the 3rd quarter. Achmea Investment Management B.V. now owns 7,231 shares of the specialty pharmaceutical company’s stock valued at $1,056,000 after acquiring an additional 5,338 shares during the period. Virginia Retirement Systems ET AL raised its stake in Jazz Pharmaceuticals PLC by 633.8% in the 3rd quarter. Virginia Retirement Systems ET AL now owns 97,600 shares of the specialty pharmaceutical company’s stock valued at $14,274,000 after acquiring an additional 84,300 shares during the period. Legal & General Group Plc raised its stake in Jazz Pharmaceuticals PLC by 1.2% in the 3rd quarter. Legal & General Group Plc now owns 234,667 shares of the specialty pharmaceutical company’s stock valued at $34,321,000 after acquiring an additional 2,829 shares during the period. Finally, Amundi Pioneer Asset Management Inc. raised its stake in Jazz Pharmaceuticals PLC by 6.6% in the 3rd quarter. Amundi Pioneer Asset Management Inc. now owns 891,322 shares of the specialty pharmaceutical company’s stock valued at $130,356,000 after acquiring an additional 54,895 shares during the period. Institutional investors and hedge funds own 88.52% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.